Skip to main content
. 2020 Dec 7;4(23):5966–5975. doi: 10.1182/bloodadvances.2020003170

Table 3.

COVID-19–specific therapies received

n (%)
Hydroxychloroquine 76 (64)
Azithromycin 59 (50)
Tocilizumab 15 (13)
Lopinavir and ritonavir 12 (10)
Convalescent plasma 11 (9)
Favipravir 11 (9)
Remdesivir 5 (4)
IVIG 4 (3)
Chloroquine 3 (3)
Other/unknown 39 (33)